The Patent Finder
ET

Entrada Therapeutics, Inc.

First filing 2016
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Previously recorded as Cycloporters, Inc. (to 2018)

Eight patents currently held, every record listed here

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in May 2035. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2035
Next term end
4
Patent families

When these terms end

Each bar runs from grant to computed term end. 2020 to 2043.
US 11,225,506 Cell Penetrating Peptides and Methods of Making and Using Thereof May 21, 2035
US 10,815,276 Cell Penetrating Peptides and Methods of Making and Using Thereof Mar 21, 2036
US 10,626,147 Cell Penetrating Peptides and Methods of Making and Using Thereof Jun 10, 2036
US 11,168,310 Compositions and Methods for Treating Mitochondrial Neurogastrointestinal Encephalopathy Feb 22, 2039
US 12,698,482 Compositions and Methods for Treating Mitochondrial Neurogastrointestinal Encephalopathy Feb 22, 2039
US 11,987,821 Compositions and Methods for Treating Mitochondrial Neurogastrointestinal Encephalopathy Aug 30, 2039
US 12,378,267 Synthesis of Fmoc-Protected Morpholino Monomers and Oligomers Jun 10, 2042
US 12,741,989 Compositions for Delivery of Antisense Compounds May 18, 2043
20252030203520402043
20 pending applications: term is not computable until grant.Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Oct 21, 2027
    The maintenance fee for Cell Penetrating Peptides and Methods of Making and Using Thereof (US 10,626,147) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 21, 2026

What they patent

The 3 largest of its 4 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 8 of 8

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 11,225,506Cell Penetrating Peptides and Methods of Making and Using Thereof
In force
 · High confidence
In forceHigh confidence
US 10,815,276Cell Penetrating Peptides and Methods of Making and Using Thereof
In force
 · High confidence
In forceHigh confidence
US 10,626,147Cell Penetrating Peptides and Methods of Making and Using Thereof
In force
 · High confidence
In forceHigh confidence
US 11,168,310Compositions and Methods for Treating Mitochondrial Neurogastrointestinal Encephalopathy
In force
 · Medium confidence
In forceMedium confidence
US 12,698,482Compositions and Methods for Treating Mitochondrial Neurogastrointestinal Encephalopathy
In force
 · Low confidence
In forceLow confidence
US 11,987,821Compositions and Methods for Treating Mitochondrial Neurogastrointestinal Encephalopathy
In force
 · Medium confidence
In forceMedium confidence
US 12,378,267Synthesis of Fmoc-Protected Morpholino Monomers and Oligomers
In force
 · High confidence
In forceHigh confidence
US 12,741,989Compositions for Delivery of Antisense Compounds
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 8: 20 applications pending · 4 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited